Those with severe COVID-19 less likely to develop monoclonal antibodies - study
“Monoclonal antibodies should first go to patients at the highest risk of death from COVID-19, but the opposite happened."
The exterior of The Department of Chemistry and Chemical Biology at Harvard University.(photo credit: REUTERS/KATHERINE TAYLOR/FILE PHOTO)ByJERUSALEM POST STAFFUpdated:
